Interested in meeting with us?
About Our Team
Co-founder, President, CEO
Antony Koblish is a medical device entrepreneur with 25 years of experience in health care. Prior to founding TELA Bio, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. During his tenure as Chief Executive Officer of Orthovita from 2002 to 2011, Mr. Koblish created significant company value, growing valuation from $30M to a $316M exit sale to Stryker Corporation in 2011. He is a skilled leader with a proven track record in driving sales growth, building a robust product pipeline, establishing world-class commercial operations, and instilling clinical and manufacturing quality. Mr. Koblish is also a co-founder and currently serves as Chairman of the Board of Onkos Surgical, Inc., a surgical oncology company, and is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and health care services companies. Mr. Koblish earned a Master of Science in Engineering degree in Mechanical Engineering and Applied Mechanics from the University of Pennsylvania and holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.
Skott Greenhalgh, PhD
Skott Greenhalgh has 20 years of industrial experience, 18 years in the development and manufacturing of medical devices, and two years of teaching and research at North Carolina State University and Philadelphia University. Dr. Greenhalgh has a strong understanding of the medical device clinical and regulatory pathways, and he has lead teams of highly skilled research and development personnel focused on cardiovascular, general surgical, and orthopedic medical device implants. Dr. Greenhalgh has developed multiple hybrid biologic implant devices, with numerous patents issued. He has directed research and development activities for multiple strategic partnerships and co-development programs, including minimally invasive cardiovascular, spinal, surgical, and neurologic implants with multiple start-ups and Fortune 500 medical device companies, and has raised more than $19M in outside capital to fund these efforts. He has licensed 14 medical implant technologies, 10 of which he was initial inventor/creator, and sold one company. Dr. Greenhalgh received his PhD in Fiber and Polymer Science and his master's degree in Textile Engineering from North Carolina State University. His Bachelor of Science degree in Mechanical Engineering is from Drexel University.
Peter Murphy has more than 20 years of commercial sales and marketing experience at leading medical device and pharmaceutical companies. Prior to joining TELA Bio, Mr. Murphy held the position of Vice President of Sales at Pacira Pharmaceuticals, Inc. where he led the domestic sales team to significant year-over-year growth with their core drug therapy, EXPAREL®. In addition, Mr. Murphy spent over a decade in the orthopedic space where he held various sales management roles within Stryker Corporation and Medtronic Spine and Biologics. During this time, Mr. Murphy successfully supported the commercialization and market growth of several advanced orthopedic biomaterials including the recombinant human growth factors, rhPDGF and rhBMP. Mr. Murphy graduated with a Bachelor of Arts degree in Business from Gettysburg College.
Paul Talmo possesses over 20 years of experience commercializing technologies within the medical device and service industries including medical devices, implantable materials, as well as imaging and diagnostic technologies and services. Mr. Talmo spent 16 years at LifeCell Corporation and was an impetus behind the transformation of a burn focused company into a soft tissue reconstruction company. Mr. Talmo was responsible for first introducing biologic materials to the urogynecology market, for urinary incontinence and pelvic floor reconstruction, as well as the general surgery market, for hernia repair. Mr. Talmo also worked closely with surgeons to develop the various techniques and protocols for implant-based reconstruction with the first biologic material used in breast reconstruction, eventually commercializing the material and new techniques in the early 2000s. Mr. Talmo applies his years of clinical and commercial experience with innovative and strategic thinking to create unique disruptive business models.